share_log

Sera Prognostics | 10-K: FY2024 Annual Report

SEC ·  Mar 19 20:17

Summary by Moomoo AI

Sera Prognostics reported a net loss of $32.9 million for fiscal year 2024, compared to $36.2 million in 2023, with revenue of $77,000. The company ended the year with $68.2 million in cash, cash equivalents and marketable securities. Operating expenses decreased to $36.7 million from $40.1 million in 2023, primarily due to reduced selling and marketing costs.The company achieved significant clinical milestones for its PreTRM test, with positive results from the AVERT PRETERM TRIAL published in July 2024 showing an 18% reduction in severe neonatal morbidity and mortality. The PRIME study results presented in January 2025 demonstrated a 25% reduction in neonatal morbidity and mortality in the modified intent-to-treat population.In February 2025, Sera strengthened its financial position by completing an underwritten public offering that raised approximately $57.5 million in gross proceeds. The company continues to focus on expanding PreTRM test adoption through commercial partnerships and payer contracts, while advancing its pipeline of pregnancy-related diagnostic products and predictive analytics tools.
Sera Prognostics reported a net loss of $32.9 million for fiscal year 2024, compared to $36.2 million in 2023, with revenue of $77,000. The company ended the year with $68.2 million in cash, cash equivalents and marketable securities. Operating expenses decreased to $36.7 million from $40.1 million in 2023, primarily due to reduced selling and marketing costs.The company achieved significant clinical milestones for its PreTRM test, with positive results from the AVERT PRETERM TRIAL published in July 2024 showing an 18% reduction in severe neonatal morbidity and mortality. The PRIME study results presented in January 2025 demonstrated a 25% reduction in neonatal morbidity and mortality in the modified intent-to-treat population.In February 2025, Sera strengthened its financial position by completing an underwritten public offering that raised approximately $57.5 million in gross proceeds. The company continues to focus on expanding PreTRM test adoption through commercial partnerships and payer contracts, while advancing its pipeline of pregnancy-related diagnostic products and predictive analytics tools.
Helpful
Not Helpful

This announcement is a separate document:

Doc 1

Doc 2

Doc 3

Doc 4

Doc 5

Doc 6

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
Comment Comment · Views 312

Recommended

Related Stocks Related Stocks
Symbol Mini Chart Price
NanoVibronix
NAOV
4.4500
Outset Medical
OM
11.280
Autonomix Medical
AMIX
2.190
Modular Medical
MODD
1.050
ReShape Lifesciences
RSLS
0.6960
Log In for the Full List
Reassessing Chinese Assets
Following the introduction of China's groundbreaking DeepSeek technology, Wall Street giants have revised their investment outlooks for the Chinese market.
Discussing
Chinese stock earnings surge: Will profit sustain the rally?
🎙️Discussion1. Which sectors are likely to be market highlights this season? 2. With the government's emphasis on technological innovati Show More
Can strong earnings reports drive Chinese concept stocks to continue rising?
79%
21%
Bullish
Bearish
1243 votes
China's Two Sessions: Key Takeaways on Stock Price Movements Before and After the Meetings
On Tuesday, China's political leadership is convening at the Great Hall of the People in Beijing for the year's most significant event, known as the "Two Sessions." These closed-door meetings are the annual plenary sessions of both the National People's Congress and the Chinese People's Political Consultative Conference, typically held simultaneously in March. The sessions generally last for about ten days....